Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
School of Medicine, Auckland University, Auckland, New Zealand.
Clin Transplant. 2022 Nov;36(11):e14746. doi: 10.1111/ctr.14746. Epub 2022 Jul 27.
Mechanical circulatory support (MCS) has been widely utilized in critically ill cardiac transplant candidates. Few studies have investigated the impact of duration of MCS before heart transplantation (HTx) on long-term patient survival.
A retrospective HTx database was reviewed between 2009 and 2019. Patients who did not or did undergo MCS before HTx were categorized into two groups: (1) A (did not) and (2) B (did), respectively. A receiver operating characteristic (ROC) curve was plotted to assess the cutoff level of MCS duration before HTx in evaluating 5-year survival.
A total of 270 HTx patients (group A: 120, group B: 150) were analyzed. Group B patients had a higher percentage of blood type O, a higher incidence of resuscitation, a shorter listing duration, and a higher likelihood of having United Network for Organ Sharing (UNOS) 1A status than group A. The ROC curve revealed 24 days as a good cut-off level for determining the best MCS before HTx timing. Group B was categorized into two subgroups: (1) B1 (MCS < 24 days, n = 65) and (2) B2 (MCS > 24 days, n = 85). B2 had a higher incidence of cardiopulmonary resuscitation (CPR), hemodialysis, longer waiting time after MCS, and better ventricular assist device implantation than B1. However, the survival curves showed that B1 outcomes were significantly worse than in groups A and B2. Groups A and B2 had similar survival curves without an increased incidence of infection.
The preliminary data demonstrated that a longer duration of MCS may be associated with better outcomes than urgent HTx.
机械循环支持(MCS)已广泛应用于危重心血管移植候选者。很少有研究调查心脏移植(HTx)前 MCS 持续时间对长期患者生存的影响。
回顾了 2009 年至 2019 年期间的 HTx 回顾性数据库。未接受或接受 HTx 前 MCS 的患者分为两组:(1)A(未)和(2)B(接受)。绘制受试者工作特征(ROC)曲线,以评估 HTx 前 MCS 持续时间的截止水平,以评估 5 年生存率。
共分析了 270 例 HTx 患者(A 组:120 例,B 组:150 例)。B 组患者的血型 O 比例较高,抢救发生率较高,列入名单时间较短,且更有可能具有器官共享联合网络(UNOS)1A 状态比 A 组高。ROC 曲线显示 24 天是确定 HTx 前最佳 MCS 时机的良好截止水平。B 组进一步分为两个亚组:(1)B1(MCS<24 天,n=65)和(2)B2(MCS>24 天,n=85)。B2 心肺复苏(CPR)、血液透析、MCS 后等待时间较长、心室辅助装置植入率较高,但 B1 的生存曲线显示,B1 预后明显差于 A 组和 B2 组。A 组和 B2 组的生存曲线相似,感染发生率没有增加。
初步数据表明,较长的 MCS 持续时间可能与比紧急 HTx 更好的结果相关。